Page last updated: 2024-08-16

thalidomide and cc 3052

thalidomide has been researched along with cc 3052 in 8 studies

Research

Studies (8)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (12.50)	18.2507
2000's	3 (37.50)	29.6817
2010's	4 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cookson, S; Dalgleish, AG; Goodbourn, S; Guckian, M; Marriott, JB; Muller, G; Shire, MG; Stirling, D; Westby, M	1
Barcellini, W; Dalgleish, AG; La Maestra, L; Lazzarin, A; Marriott, JB; Zaninoni, A	1
Dalgleish, AG; Dransfield, I; Guckian, M; Hay, P	1
Clarke, IA; Dalgleish, AG; Dredge, K; Marriott, JB; Muller, G; Stirling, D	1
Ehrt, S; Fallows, D; Kaplan, G; Koo, MS; Manca, C; Muller, G; O'Brien, P; Subbian, S; Sung, N; Tsenova, L; Yang, G	1
Fallows, D; Kaplan, G; Koo, MS; Muller, G; O'Brien, P; Peixoto, B; Subbian, S; Tsenova, L; Yang, G; Zeldis, JB	1
Dartois, V; Fallows, D; Kaplan, G; Koo, MS; Muller, G; O'Brien, P; Peixoto, B; Subbian, S; Tsenova, L; Yang, G	1
Chung, SK; Lee, YK	1

Trials

1 trial(s) available for thalidomide and cc 3052

Article	Year
Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells. Clinical and experimental immunology, 2002, Volume: 130, Issue:1 Topics: Adjuvants, Immunologic; Adult; Aged; Antibodies, Monoclonal; Antigens, CD; CD3 Complex; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cells, Cultured; Enzyme-Linked Immunosorbent Assay; Female; Humans; Inflammation; Lenalidomide; Lipopolysaccharides; Lymphocyte Activation; Male; Middle Aged; Neoplasms; Phosphodiesterase Inhibitors; Receptors, Interleukin-2; Receptors, Tumor Necrosis Factor; Receptors, Tumor Necrosis Factor, Type II; Signal Transduction; Solubility; Thalidomide; Tumor Necrosis Factor-alpha	2002

Article

Year

Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells.

Clinical and experimental immunology, 2002, Volume: 130, Issue:1

Topics: Adjuvants, Immunologic; Adult; Aged; Antibodies, Monoclonal; Antigens, CD; CD3 Complex; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cells, Cultured; Enzyme-Linked Immunosorbent Assay; Female; Humans; Inflammation; Lenalidomide; Lipopolysaccharides; Lymphocyte Activation; Male; Middle Aged; Neoplasms; Phosphodiesterase Inhibitors; Receptors, Interleukin-2; Receptors, Tumor Necrosis Factor; Receptors, Tumor Necrosis Factor, Type II; Signal Transduction; Solubility; Thalidomide; Tumor Necrosis Factor-alpha

2002

Other Studies

7 other study(ies) available for thalidomide and cc 3052

Article	Year
CC-3052: a water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production. Journal of immunology (Baltimore, Md. : 1950), 1998, Oct-15, Volume: 161, Issue:8 Topics: Adjuvants, Immunologic; Animals; Humans; Immunosuppressive Agents; Leukocytes, Mononuclear; Mice; Thalidomide; Tumor Necrosis Factor-alpha	1998
The thalidomide analogue CC-3052 inhibits HIV-1 and tumour necrosis factor-alpha (TNF-alpha) expression in acutely and chronically infected cells in vitro. Clinical and experimental immunology, 2000, Volume: 119, Issue:1 Topics: Anti-HIV Agents; Base Sequence; Cell Line; DNA Primers; Gene Expression; HIV Infections; HIV-1; Humans; In Vitro Techniques; Macrophages; T-Lymphocytes; Tetradecanoylphorbol Acetate; Thalidomide; Tumor Necrosis Factor-alpha; U937 Cells	2000
Thalidomide analogue CC-3052 reduces HIV+ neutrophil apoptosis in vitro. Clinical and experimental immunology, 2000, Volume: 121, Issue:3 Topics: Adjuvants, Immunologic; Adult; Apoptosis; Cyclic AMP; Dinoprostone; Drug Synergism; Female; HIV Infections; Humans; In Vitro Techniques; Male; Middle Aged; Neutrophils; Thalidomide; Tumor Necrosis Factor-alpha	2000
Phosphodiesterase 4 inhibition reduces innate immunity and improves isoniazid clearance of Mycobacterium tuberculosis in the lungs of infected mice. PloS one, 2011, Feb-25, Volume: 6, Issue:2 Topics: Animals; Antibiotics, Antitubercular; Bacterial Load; Cyclic Nucleotide Phosphodiesterases, Type 4; Disease Models, Animal; Down-Regulation; Drug Evaluation, Preclinical; Drug Interactions; Immunity, Innate; Isoniazid; Lung; Metabolic Clearance Rate; Mice; Mice, Inbred C57BL; Molecular Sequence Data; Mycobacterium tuberculosis; Phosphodiesterase 4 Inhibitors; Thalidomide; Tuberculosis	2011
Phosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathology. The American journal of pathology, 2011, Volume: 179, Issue:1 Topics: Animals; Antitubercular Agents; Blotting, Western; Colony-Forming Units Assay; Cyclic Nucleotide Phosphodiesterases, Type 4; Cytokines; Drug Synergism; Drug Therapy, Combination; Female; Isoniazid; Lung; Macrophage Activation; Male; Matrix Metalloproteinases; Mycobacterium tuberculosis; Phosphodiesterase 4 Inhibitors; Pulmonary Fibrosis; Rabbits; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thalidomide; Tuberculosis, Pulmonary	2011
Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungs. PLoS pathogens, 2011, Volume: 7, Issue:9 Topics: Animals; Antitubercular Agents; Bacterial Load; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Drug Resistance, Bacterial; Female; Gene Expression Regulation; Isoniazid; Lung; Macrophages; Male; Mycobacterium tuberculosis; Oligonucleotide Array Sequence Analysis; Phosphodiesterase 4 Inhibitors; Rabbits; Thalidomide; Tuberculosis; Tumor Necrosis Factor-alpha	2011
The inhibitory effect of thalidomide analogue on corneal neovascularization in rabbits. Cornea, 2013, Volume: 32, Issue:8 Topics: Administration, Topical; Angiogenesis Inhibitors; Animals; Biomarkers; Corneal Neovascularization; Disease Models, Animal; Female; Male; Rabbits; Thalidomide; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A	2013